Workflow
化学制药产品
icon
Search documents
翰宇药业9月30日获融资买入7021.27万元,融资余额12.91亿元
Xin Lang Zheng Quan· 2025-10-09 01:21
截至6月30日,翰宇药业股东户数6.30万,较上期增加9.95%;人均流通股11841股,较上期减少3.98%。 2025年1月-6月,翰宇药业实现营业收入5.49亿元,同比增长114.86%;归母净利润1.45亿元,同比增长 1504.30%。 分红方面,翰宇药业A股上市后累计派现4.17亿元。近三年,累计派现0.00元。 机构持仓方面,截止2025年6月30日,翰宇药业十大流通股东中,香港中央结算有限公司位居第五大流 通股东,持股768.17万股,相比上期减少38.64万股。 责任编辑:小浪快报 9月30日,翰宇药业涨1.52%,成交额6.89亿元。两融数据显示,当日翰宇药业获融资买入额7021.27万 元,融资偿还9334.25万元,融资净买入-2312.98万元。截至9月30日,翰宇药业融资融券余额合计12.91 亿元。 融资方面,翰宇药业当日融资买入7021.27万元。当前融资余额12.91亿元,占流通市值的6.85%,融资 余额超过近一年80%分位水平,处于高位。 融券方面,翰宇药业9月30日融券偿还0.00股,融券卖出0.00股,按当日收盘价计算,卖出金额0.00元; 融券余量0.00股,融券余 ...
奥赛康股价微跌0.68% 股东拟减持1856万股
Jin Rong Jie· 2025-08-15 16:53
Core Viewpoint - Aosaikang's stock price experienced a decline on August 15, closing at 26.35 yuan, down 0.68% from the previous trading day [1] Company Overview - Aosaikang's main business is in the pharmaceutical manufacturing industry, accounting for 97.92% of its operations [1] - The company is involved in the chemical pharmaceutical sector and has capabilities in innovative drug research and development [1] Financial Performance - In the first quarter of 2025, Aosaikang achieved a revenue of 509 million yuan and a net profit of 54.73 million yuan [1] Shareholder Activity - The major shareholder, Yiwai Holdings Co., Ltd., plans to reduce its stake by up to 18.56 million shares, representing 2% of the total share capital, starting from September 6 for three months [1] - Yiwai currently holds approximately 120 million shares, which is 12.95% of the total share capital [1] Market Activity - On August 15, the net inflow of main funds was 3.49 million yuan, accounting for 0.01% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 16.62 million yuan, representing 0.07% of the circulating market value [1]